FAQS FOR NON-GENETICS HEALTH CARE PROFESSIONALS ON
INFORMED CONSENT FOR INHERITED (GERMLINE) AND TUMOUR (SOMATIC) BRCA TESTING

1. **Which patients** should be considered for germline and tumour BRCA (refers to BRCA 1 & BRCA 2) testing in relation to the PARP inhibitor olaparib?

2. **When** should I discuss these tests with my patient?

3. What is the **likelihood** of finding a germline and/or tumour BRCA pathogenic variant in my patient?

4. What are the **implications for my patient** of identifying a germline BRCA pathogenic variant?

5. What are the **implications for my patient’s family** of finding a germline BRCA pathogenic variant and how is this managed?

6. What are the **implications for my patient and their family** of finding a tumour BRCA pathogenic variant?

7. What are the **issues I should discuss** with my patient as part of the informed consent process?

8. Is **written consent** required?

9. What **patient information** materials are available for my patient?

10. Who will give my patient the **results**?

11. **Who else** will have access to the results?

12. Can the test results be **inconclusive**? What are the implications of inconclusive results?

13. What are the implications of finding **no BRCA pathogenic variant** in my patient’s blood or tissue sample?

14. Are there **other cancer predisposition genes** I should consider in my patient?
1. Which patients should be considered for germline and tissue BRCA testing in relation to the PARP inhibitor olaparib?

Germline and tumour BRCA testing should be considered in

- those who have a diagnosis of advanced (FIGO stages III and IV) high grade epithelial ovarian, primary peritoneal or fallopian tube cancer AND are commencing first-line platinum based chemotherapy. They should have no contraindication to the use of olaparib as maintenance therapy.

- those who have a diagnosis of high grade serous epithelial ovarian cancer, primary peritoneal or fallopian tube cancer AND have previously responded to platinum-based therapy AND have relapsed and are commencing a second or subsequent line platinum-based treatment. They should have no contraindication to the use of olaparib as maintenance therapy.

- those who have a diagnosis of metastatic castration-resistant prostate cancer and have progressed following prior hormonal therapy that included a new hormonal agent

If the patient has previously undergone germline BRCA testing, there is no need for that to be repeated and tumour testing only needs to be done.

If you have a query regarding the result of a BRCA test carried out in the past, e.g. if there is no record of the result or the test found a ‘variant of uncertain significance’ (VUS), you should contact the Cancer Genetics Service to discuss this.

Note in a patient who has previously undergone a bone marrow transplant, a blood sample cannot be used for germline testing. They should be referred to the genetics service to arrange appropriate testing.

2. When should I discuss these tests with my patient?

Ovarian Cancer
First Line Maintenance Treatment
If clinically indicated, olaparib should be commenced as maintenance treatment within eight weeks of completion of platinum-based therapy (See NCCP national chemotherapy regimens for ovarian cancer).

- Note; Where debulking surgery is required, the last dose of platinum chemotherapy should be within 12 weeks of starting olaparib maintenance
Given the test turnaround time of up to 6\textsuperscript{1} weeks, germline BRCA1/2 testing should be offered to potentially eligible patients at the time of commencement of first line platinum treatment.

**Platinum Sensitive Relapsed Maintenance treatment**

If clinically indicated, olaparib should be commenced as maintenance treatment within eight weeks of completion of a second line course of platinum-based therapy (See NCCP national chemotherapy regimens for ovarian cancer). Given the test turnaround time of up to 6\textsuperscript{1} weeks, germline BRCA1/2 testing should be offered to potentially eligible patients at the time of relapse following first line platinum treatment and treatment planning for the second or subsequent line of platinum treatment.

A number of patients may subsequently not respond to their platinum-based therapy, in which case they will not proceed to olaparib maintenance therapy, regardless of their BRCA test result.

**Prostate Cancer**

Where a patient meets the eligibility criteria detailed in the national chemotherapy regimen and is being considered for treatment for olaparib the following testing algorithm should be used;

Testing for tBRCA and MLPA should be carried out with reflex gBRCA testing\textsuperscript{2} of patients who test positive for tBRCA

- Where a suitable tumour sample is not available for testing the patient can be offered gBRCA testing\textsuperscript{2}
  - Or
- Where a tBRCA test fails (due to sample) reflex gBRCA testing\textsuperscript{2} may be carried out and the case will be referred back to the prescribing Consultant Medical Oncologist to determine next steps

3. What is the likelihood of finding a germline and/or a tumour BRCA pathogenic variant in my patient?

The frequency of germline and tumour BRCA pathogenic variants is up to 38%\textsuperscript{3} and 8.5-10%\textsuperscript{4}, respectively in patients with platinum-sensitive recurrent high-grade serous ovarian cancer.

---

\textsuperscript{1} 90\% of test results within this turnaround time of 6 weeks

\textsuperscript{2} In line with consent given


\textsuperscript{3} https://d1ijoxgr27nf.cloudfront.net/research-divisions/protocol-3-brca-mutation-carrier-20150209-v4.pdf?sfvrsn=5e7f6f69_2
With regard to patients with metastatic castration resistant prostate cancer, alterations in BRCA1 and BRCA2 are some of the most prevalent homologous recombinant repair (HRR) mutations occurring in approximately 10% of patients.

4. What are the implications for my patient with ovarian/prostate cancer of identifying a germline BRCA pathogenic variant?

The implications in relation to personal cancer risk are an increased risk of other cancers, particularly breast cancer. There can also be an increased risk of melanoma, pancreatic and other BRCA related cancers.

As it is an inherited cancer predisposition, there are implications for biological (blood) male and female relatives who may also carry the gene.

A woman with a BRCA1 gene pathogenic variant has a lifetime risk (to 80yrs) of breast cancer of up to 90% and a lifetime risk of ovarian cancer of up to 60%. A woman with a BRCA2 pathogenic variant has a lifetime risk of breast cancer of up to 85% and a lifetime risk of ovarian cancer of up to 30%. There are other cancers that may arise in individuals with variants (mutations) in these genes but the lifetime risk of developing these is much lower.

The measures that can be taken to reduce these risks include prophylactic surgery (bilateral mastectomy and/or bilateral salpingo-oophorectomy (surgery to remove fallopian tubes and ovaries). Breast surveillance with MRI +/- mammography is recommended for women with a BRCA pathogenic variant who have not had prophylactic surgery. There is currently no recommended ovarian surveillance.

A man with a BRCA2 gene pathogenic variant may have a 5–10% lifetime risk of breast cancer and a 25–30% lifetime risk of prostate cancer. A man with BRCA1 pathogenic variant has a 0.1–1% risk of breast cancer and a prostate cancer risk which is similar to (or may be slightly more than) the population risk.

With your patient’s agreement referral to genetic services (enclosing a copy of the genetic result) is recommended, and the effect of a BRCA pathogenic variant on personal cancer risk and the approach to informing relatives would be addressed in more detail at the cancer genetics consultation.

5. What are the implications for my patient’s family of finding a germline BRCA pathogenic variant and how is this managed?

If your patient is found to have a germline BRCA pathogenic variant, then it is likely that this has been inherited and that biological (blood) relatives – both males and females, could also carry the BRCA

---

6 BRCA1 and BRCA2 — Knowledge Hub (hee.nhs.uk)
variant and be at risk of BRCA associated cancers (including those referred to above and male breast cancer). Those currently unaffected by cancer could still harbour the BRCA variant.

During the consent process, sharing results with family members will have been discussed and recorded, (most patients are happy to do so). The patient should be reminded of this when results are communicated. The patient should firstly share the genetic BRCA test result with her first degree relatives (parents, siblings, children), given the implications this may have for both male and female relatives who may wish to be tested. Typically, during her consultation with the clinical genetics service, disclosure to relatives will be discussed and the patient may be given a ‘to whom it may concern’ letter that she may use to disseminate the information to her first degree relatives if she prefers.

The patient’s relatives should not be offered testing through the olaparib testing pathway and should be offered genetic counselling by the Cancer Genetics Service in advance of testing. This testing of unaffected relatives is known as predictive or cascade screening and must be preceded by genetic counselling by a qualified genetic counsellor or genetic consultant.

6. What are the implications for my patient and their family of identifying a tumour BRCA pathogenic variant?

A patient with a tumour BRCA pathogenic variant is more likely to respond to PARP inhibitor therapy and is eligible for treatment with olaparib.

Both a germline and tumour BRCA test are required to determine that the variant is a tumour variant only.

If the variant is found solely in the patient’s tumour, then it is unlikely to be inherited. As such, tumour variants are unlikely to confer any additional cancer risk to either the individual or to their families. The additional risks are conferred with a germline variant.

7. What are the issues I should discuss with my patient as part of the informed consent process?

In summary, the following issues should be discussed: the purpose of the tests in relation to their choice of treatment; the possibility that they may be found to have an inherited cancer predisposition and if so, that it could have been inherited by other family members also; the protections offered by Irish law in relation to use of genetic results; the possibility that a test may be inconclusive.

- The purpose of the tests is to check for a germline or tumour pathogenic variant in BRCA genes, which would predict likelihood of response to olaparib.
- Possible results
  1. A germline BRCA pathogenic variant is identified
  2. A tumour BRCA pathogenic variant is identified
  3. A germline and tumour BRCA pathogenic variant is identified
4. A germline ‘variant of uncertain (or unknown) significance’ (VUS) identified
5. A germline ‘variant of uncertain significance’ (VUS) plus tumour BRCA pathogenic variant is identified
6. No germline or tumour pathogenic variants are identified

Note: Tumour BRCA variant is identified and germline status is not determined

- There may still be a genetic explanation for your patient’s cancer as they could have a variant in a gene not tested for or unknown at this time and there may be circumstances that would warrant referral to genetic services.
- Discuss the benefits, risks, implications and limitations of the test e.g. test sensitivity and specificity and impact on blood relatives.
- Discuss consent that the genetic test may be used for the benefit of other family members and made available for use in genetic counselling of other family members attending genetic centres, if requested.
- Discuss consent to communicate the genetic result to the GP and/or other healthcare professionals involved in the patient’s care.
- Discuss consent that DNA may be stored indefinitely at the testing laboratory and/or other testing centres.
- Discuss consent that the DNA may be used confidentially for quality assurance purposes.
- Under the provisions of Part 4 of the Disability Act 2005, an insurer cannot request, take into account or process the results of genetic tests.

8. Is written consent required?

Yes, written consent is a requirement for genetic testing. Evidence of written consent may accompany the blood and tissue samples and may be incorporated into the order request forms for germline and tumour BRCA testing. A copy of the test request-consent forms should also be held locally in the patient’s medical record.

9. What patient information materials are available for my patient?

Patient information leaflets for BRCA testing via this pathway for ovarian and prostate cancer are available on the NCCP website www.hse.ie/nccpchemoregimens or direct link here. This should be provided to all patients offered the test.

10. Who will give my patient the results?

The result will be emailed to you, the ordering clinician, at the email address you provide on the test request form. You should explain the result to the patient, its implications for olaparib eligibility, and recommendation for referral to the Cancer Genetics Service if indicated.
Patients with an identified germline pathogenic variant or a germline ‘variant of uncertain significance’, (VUS), should be referred with the patient’s agreement to the cancer genetics service, where they will be prioritised for review. Those in whom no germline pathogenic variant is found should still be offered a referral to the genetics service if there is a separate indication e.g. a patient with multiple primary cancers, young age of cancer onset or a strong family history such as a number of first degree relatives with breast/ovarian prostate or bowel cancer.

11. **Who else** will have access to the result?

The germline test result (including if no pathogenic variant has been found) can be used by genetics health care professionals dealing with their relatives, if the patient has consented to this. This is therefore included in the test request-consent form.

12. Can the test result be inconclusive? What are the implications of an inconclusive result?

Yes, it is possible that a germline ‘variant of uncertain significance’ (VUS) is identified, meaning the implication of the variant in their BRCA gene is unclear. In this case the patient is not eligible for olaparib. The patient should be offered a referral to the Cancer Genetics Service to discuss their result.

It is also possible that the tumour BRCA variant test fails, either owing to insufficient quantity/quality of tumour DNA, or failure to meet the test’s quality control criteria. In this case, full germline BRCA variant sequencing can be performed to assess for germline BRCA variants only.

13. What are the implications of a finding of no BRCA pathogenic variant in my patient?

If no pathogenic variant has been identified either germline or tumour, the patient is not eligible for olaparib. Referral to the genetics service should only be made if there is a separate indication e.g. a patient with multiple primary cancers, young age of cancer onset or a strong family history such as a number of first degree relatives with breast/ovarian, prostate or bowel cancer.

14. Are there other cancer predisposition genes I should consider in my patient?

If a patient has multiple primary cancers, young age of cancer onset or a strong family history such as a number of first degree relatives with breast/ovarian, prostate or bowel cancer, they should be referred to the genetics service for a more detailed risk assessment and possible further genetic testing. These additional test results would not affect choice of systemic therapy for their ovarian/prostate cancer.

If you need to discuss a patient, please contact the Cancer Genetics Services, St. James’s Hospital, Dublin 8, Tel:- 01-4103759